Flexible Stenting Solutions (FSS) has enrolled the first patients in two trials of its FlexStent, a femoropopliteal stent and delivery system.

The two trials are the Japan FlexStent clinical trial and the US FlexStent OPEN trial in Belgium.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The prospective, multicentre and randomised Japan FlexStent clinical trial will enrol 100 patients and compare the FlexStent with balloon angioplasty.

The company hopes that the system will improve patient care in the high growth peripheral vascular segment.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact